INDUSTRY OVERVIEW
The Neglected Tropical Disease Treatment is Growing at 9.10% and is expected to reach USD8.3Billion by 2033. Below mentioned are some of the dynamics shaping the Neglected Tropical Disease Treatment.Neglected Tropical Disease Treatment Market Size in (USD Billion) CAGR Growth Rate 9.10%
| Study Period | 2020-2033 |
| Market Size (2025): | USD4.1Billion |
| Market Size (2033): | USD8.3Billion |
| CAGR (2025 - 2033): | 9.10% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | Africa |
www.htfmarketinsights.com
Neglected Tropical Disease (NTD) treatments address conditions like Chagas disease, Leishmaniasis, and Lymphatic Filariasis that primarily affect low-income populations in tropical areas. Treatments include antiparasitic drugs, vaccines, and antibiotic regimens. Despite low commercial return, global health organizations and governments support R&D and distribution through donations and policy. Advances in single-dose drugs and preventive care are reshaping delivery.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Regulatory Landscape
- WHO and Gavi frameworks drive funding, drug approvals, and vaccination rollouts.
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- High Disease Burden In Low-income Regions
- international Health Funding
- increased R&D In Tropical Medicine
- WHO Initiatives
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Limited Commercial Incentives
- drug Resistance
- poor Infrastructure
- high Treatment Costs
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Public-private partnerships
- drug repurposing
- vaccine pipeline growth
- digital disease tracking
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Orphan Drug Status Support
- AI In Drug Discovery
- donor-funded Distribution
- innovation In Point-of-care Delivery
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Anthelmintics
- Antiprotozoals
- Antibiotics
- Vaccines
Neglected Tropical Disease Treatment Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Schistosomiasis
- Chagas disease
- Leishmaniasis
- Lymphatic filariasis
- Onchocerciasis
Neglected Tropical Disease Treatment Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The Africa currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia-Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
Dominating Region
Africa
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- GlaxoSmithKline (UK)
- Merck & Co. (USA)
- Johnson & Johnson (USA)
- Sanofi (France)
- Novartis (Switzerland)
- Eisai Co. (Japan)
- Cipla (India)
- Bayer (Germany)
- PATH (USA)
- DNDi (Switzerland)
- AbbVie (USA)
- Takeda Pharmaceutical (Japan)
- Glenmark Pharmaceuticals (India)
- Amneal Pharmaceuticals (USA)
Neglected Tropical Disease Treatment Market Segmentation by Players
www.htfmarketinsights.com
Regional Analysis
- High focus in Sub-Saharan Africa, Latin America, and Southeast Asia.
Market Entropy
- July 2025: GSK announced a new oral formulation targeting lymphatic filariasis, aiming for accelerated rollout across Southeast Asia and Sub-Saharan Africa.
Merger & Acquisition
- May 2025 – GSK acquired a biotech focused on tropical parasitic infections. In June, GSK launched a fast-track program for new oral treatment candidates for Chagas disease and leishmaniasis.
Regulatory Landscape
- WHO and Gavi frameworks drive funding, drug approvals, and vaccination rollouts.
Patent Analysis
- Rising patent filings for novel antiparasitic agents and heat-stable vaccines.
Investment and Funding Scenario
- Bill & Melinda Gates Foundation and CEPI increase targeted funding.
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2025 |
|
Based Year Market Size (2023) |
USD4.1Billion |
|
Historical Period |
2020 to 2025 |
|
CAGR (2025 to 2033) |
9.10% |
|
Forecast Period |
2025 to 2033 |
|
Forecasted Period Market Size (2033) |
USD8.3Billion |
|
Scope of the Report |
Segmentation by Type Anthelmintics,Antiprotozoals,Antibiotics,Vaccines, Segmentation by Application Schistosomiasis,Chagas disease,Leishmaniasis,Lymphatic filariasis,Onchocerciasis, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
GlaxoSmithKline (UK),Merck & Co. (USA),Johnson & Johnson (USA),Sanofi (France),Novartis (Switzerland),Eisai Co. (Japan),Cipla (India),Bayer (Germany),PATH (USA),DNDi (Switzerland),AbbVie (USA),Takeda Pharmaceutical (Japan),Glenmark Pharmaceuticals (India),Amneal Pharmaceuticals (USA) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Neglected Tropical Disease Treatment - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Neglected Tropical Disease Treatment Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Neglected Tropical Disease Treatment Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Neglected Tropical Disease Treatment Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 High disease burden in low-income regions
- 3.1.2 international health funding
- 3.1.3 increased R&D in tropical medicine
- 3.1.4 WHO initiatives
-
3.2 Available Opportunities
- 3.2.1 Orphan drug status support
- 3.2.2 AI in drug discovery
- 3.2.3 donor-funded distribution
- 3.2.4 innovation in point-of-care del
-
3.3 Influencing Trends
- 3.3.1 Public-private partnerships
- 3.3.2 drug repurposing
- 3.3.3 vaccine pipeline growth
- 3.3.4 digital disease tracking
- 3.3.5 targeted ve
-
3.4 Challenges
- 3.4.1 Limited commercial incentives
- 3.4.2 drug resistance
- 3.4.3 poor infrastructure
- 3.4.4 high treatment costs
- 3.4.5 delayed regulatory
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Neglected Tropical Disease Treatment Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Neglected Tropical Disease Treatment Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Neglected Tropical Disease Treatment : Competition Benchmarking & Performance Evaluation
- 5.1 Global Neglected Tropical Disease Treatment Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Neglected Tropical Disease Treatment Revenue 2025
- 5.3 Global Neglected Tropical Disease Treatment Sales Volume by Manufacturers (2025)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 5C’s Analysis
- 5.6 Ansoff Matrix
Chapter 6: Global Neglected Tropical Disease Treatment Market: Company Profiles
- 6.1 GlaxoSmithKline (UK)
- 6.1.1 GlaxoSmithKline (UK) Company Overview
- 6.1.2 GlaxoSmithKline (UK) Product/Service Portfolio & Specifications
- 6.1.3 GlaxoSmithKline (UK) Key Financial Metrics
- 6.1.4 GlaxoSmithKline (UK) SWOT Analysis
- 6.1.5 GlaxoSmithKline (UK) Development Activities
- 6.2 Merck & Co. (USA)
- 6.3 Johnson & Johnson (USA)
- 6.4 Sanofi (France)
- 6.5 Novartis (Switzerland)
- 6.6 Eisai Co. (Japan)
- 6.7 Cipla (India)
- 6.8 Bayer (Germany)
- 6.9 PATH (USA)
- 6.10 DNDi (Switzerland)
- 6.11 AbbVie (USA)
- 6.12 Takeda Pharmaceutical (Japan)
- 6.13 Glenmark Pharmaceuticals (India)
- 6.14 Amneal Pharmaceuticals (USA)
- 6.15 MedinCell (France)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Neglected Tropical Disease Treatment by Type & Application (2020-2033)
-
7.1 Global Neglected Tropical Disease Treatment Market Revenue Analysis (USD Million) by Type (2020-2025)
- 7.1.1 Anthelmintics
- 7.1.2 Antiprotozoals
- 7.1.3 Antibiotics
- 7.1.4 Vaccines
- 7.1.5 Combination Therapies
-
7.2 Global Neglected Tropical Disease Treatment Market Revenue Analysis (USD Million) by Application (2020-2025)
- 7.2.1 Schistosomiasis
- 7.2.2 Chagas Disease
- 7.2.3 Leishmaniasis
- 7.2.4 Lymphatic Filariasis
- 7.2.5 Onchocerciasis
- 7.3 Global Neglected Tropical Disease Treatment Market Revenue Analysis (USD Million) by Type (2025-2033)
- 7.4 Global Neglected Tropical Disease Treatment Market Revenue Analysis (USD Million) by Application (2025-2033)
Chapter 8 : North America Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 8.1 North America Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 8.2.1 Anthelmintics
- 8.2.2 Antiprotozoals
- 8.2.3 Antibiotics
- 8.2.4 Vaccines
- 8.2.5 Combination Therapies
-
8.3 North America Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 8.3.1 Schistosomiasis
- 8.3.2 Chagas Disease
- 8.3.3 Leishmaniasis
- 8.3.4 Lymphatic Filariasis
- 8.3.5 Onchocerciasis
- 8.4 North America Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 8.5 North America Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 8.6 North America Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 9.1 LATAM Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 9.2.1 Anthelmintics
- 9.2.2 Antiprotozoals
- 9.2.3 Antibiotics
- 9.2.4 Vaccines
- 9.2.5 Combination Therapies
-
9.3 LATAM Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 9.3.1 Schistosomiasis
- 9.3.2 Chagas Disease
- 9.3.3 Leishmaniasis
- 9.3.4 Lymphatic Filariasis
- 9.3.5 Onchocerciasis
- 9.4 LATAM Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 9.5 LATAM Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 9.6 LATAM Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 10 : West Europe Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 10.1 West Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 10.2.1 Anthelmintics
- 10.2.2 Antiprotozoals
- 10.2.3 Antibiotics
- 10.2.4 Vaccines
- 10.2.5 Combination Therapies
-
10.3 West Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 10.3.1 Schistosomiasis
- 10.3.2 Chagas Disease
- 10.3.3 Leishmaniasis
- 10.3.4 Lymphatic Filariasis
- 10.3.5 Onchocerciasis
- 10.4 West Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 10.5 West Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 10.6 West Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 11 : Central & Eastern Europe Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 11.2.1 Anthelmintics
- 11.2.2 Antiprotozoals
- 11.2.3 Antibiotics
- 11.2.4 Vaccines
- 11.2.5 Combination Therapies
-
11.3 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 11.3.1 Schistosomiasis
- 11.3.2 Chagas Disease
- 11.3.3 Leishmaniasis
- 11.3.4 Lymphatic Filariasis
- 11.3.5 Onchocerciasis
- 11.4 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 11.5 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 11.6 Central & Eastern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 12 : Northern Europe Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 12.2.1 Anthelmintics
- 12.2.2 Antiprotozoals
- 12.2.3 Antibiotics
- 12.2.4 Vaccines
- 12.2.5 Combination Therapies
-
12.3 Northern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 12.3.1 Schistosomiasis
- 12.3.2 Chagas Disease
- 12.3.3 Leishmaniasis
- 12.3.4 Lymphatic Filariasis
- 12.3.5 Onchocerciasis
- 12.4 Northern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 12.5 Northern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 12.6 Northern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 13 : Southern Europe Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 13.2.1 Anthelmintics
- 13.2.2 Antiprotozoals
- 13.2.3 Antibiotics
- 13.2.4 Vaccines
- 13.2.5 Combination Therapies
-
13.3 Southern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 13.3.1 Schistosomiasis
- 13.3.2 Chagas Disease
- 13.3.3 Leishmaniasis
- 13.3.4 Lymphatic Filariasis
- 13.3.5 Onchocerciasis
- 13.4 Southern Europe Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 13.5 Southern Europe Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 13.6 Southern Europe Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 14 : East Asia Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 14.1 East Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 14.2.1 Anthelmintics
- 14.2.2 Antiprotozoals
- 14.2.3 Antibiotics
- 14.2.4 Vaccines
- 14.2.5 Combination Therapies
-
14.3 East Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 14.3.1 Schistosomiasis
- 14.3.2 Chagas Disease
- 14.3.3 Leishmaniasis
- 14.3.4 Lymphatic Filariasis
- 14.3.5 Onchocerciasis
- 14.4 East Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 14.5 East Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 14.6 East Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 15 : Southeast Asia Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 15.2.1 Anthelmintics
- 15.2.2 Antiprotozoals
- 15.2.3 Antibiotics
- 15.2.4 Vaccines
- 15.2.5 Combination Therapies
-
15.3 Southeast Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 15.3.1 Schistosomiasis
- 15.3.2 Chagas Disease
- 15.3.3 Leishmaniasis
- 15.3.4 Lymphatic Filariasis
- 15.3.5 Onchocerciasis
- 15.4 Southeast Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 15.5 Southeast Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 15.6 Southeast Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 16 : South Asia Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 16.1 South Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 16.2.1 Anthelmintics
- 16.2.2 Antiprotozoals
- 16.2.3 Antibiotics
- 16.2.4 Vaccines
- 16.2.5 Combination Therapies
-
16.3 South Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 16.3.1 Schistosomiasis
- 16.3.2 Chagas Disease
- 16.3.3 Leishmaniasis
- 16.3.4 Lymphatic Filariasis
- 16.3.5 Onchocerciasis
- 16.4 South Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 16.5 South Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 16.6 South Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 17 : Central Asia Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 17.1 Central Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 17.2.1 Anthelmintics
- 17.2.2 Antiprotozoals
- 17.2.3 Antibiotics
- 17.2.4 Vaccines
- 17.2.5 Combination Therapies
-
17.3 Central Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 17.3.1 Schistosomiasis
- 17.3.2 Chagas Disease
- 17.3.3 Leishmaniasis
- 17.3.4 Lymphatic Filariasis
- 17.3.5 Onchocerciasis
- 17.4 Central Asia Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 17.5 Central Asia Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 17.6 Central Asia Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 18 : Oceania Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 18.1 Oceania Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 18.2.1 Anthelmintics
- 18.2.2 Antiprotozoals
- 18.2.3 Antibiotics
- 18.2.4 Vaccines
- 18.2.5 Combination Therapies
-
18.3 Oceania Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 18.3.1 Schistosomiasis
- 18.3.2 Chagas Disease
- 18.3.3 Leishmaniasis
- 18.3.4 Lymphatic Filariasis
- 18.3.5 Onchocerciasis
- 18.4 Oceania Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 18.5 Oceania Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 18.6 Oceania Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 19 : MEA Neglected Tropical Disease Treatment Market Breakdown by Country, Type & Application
- 19.1 MEA Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 19.2.1 Anthelmintics
- 19.2.2 Antiprotozoals
- 19.2.3 Antibiotics
- 19.2.4 Vaccines
- 19.2.5 Combination Therapies
-
19.3 MEA Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 19.3.1 Schistosomiasis
- 19.3.2 Chagas Disease
- 19.3.3 Leishmaniasis
- 19.3.4 Lymphatic Filariasis
- 19.3.5 Onchocerciasis
- 19.4 MEA Neglected Tropical Disease Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 19.5 MEA Neglected Tropical Disease Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 19.6 MEA Neglected Tropical Disease Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Neglected Tropical Disease Treatment Market is growing at a steady pace over the last few years and is expected to grow at a CAGR of 9.10% from 2025 to 2033 to reach a market size of 9.10% USD 8.3 Billion
The Neglected Tropical Disease Treatment Market is predicted to grow at a CAGR of 9.10%.
Some of the prominent trends that are influencing and driving the growth of Global Neglected Tropical Disease Treatment Market are Public-private Partnerships,drug Repurposing,vaccine Pipeline Growth,digital Disease Tracking,targeted Vector Control Strategies
The leaders in the Global Neglected Tropical Disease Treatment Market such as GlaxoSmithKline (UK),Merck & Co. (USA),Johnson & Johnson (USA),Sanofi (France),Novartis (Switzerland),Eisai Co. (Japan),Cipla (India),Bayer (Germany),PATH (USA),DNDi (Switzerland),AbbVie (USA),Takeda Pharmaceutical (Japan),Glenmark Pharmaceuticals (India),Amneal Pharmaceuticals (USA),MedinCell (France) are targeting innovative and differentiated growth drivers some of them are High Disease Burden In Low-income Regions,international Health Funding,increased R&D In Tropical Medicine,WHO Initiatives,climate Change Effects
Some of the major challanges seen in Global Neglected Tropical Disease Treatment Market are Limited Commercial Incentives,drug Resistance,poor Infrastructure,high Treatment Costs,delayed Regulatory Approvals.
Some of the opportunities that Analyst at HTF MI have identified in Neglected Tropical Disease Treatment Market are:
- Orphan Drug Status Support
- AI In Drug Discovery
- donor-funded Distribution
- innovation In Point-of-care Delivery
- capacity Building In Endemic Regions
New entrants, including competitors from unrelated industries along with players such as GlaxoSmithKline (UK),Merck & Co. (USA),Johnson & Johnson (USA),Sanofi (France),Novartis (Switzerland),Eisai Co. (Japan),Cipla (India),Bayer (Germany),PATH (USA),DNDi (Switzerland),AbbVie (USA),Takeda Pharmaceutical (Japan),Glenmark Pharmaceuticals (India),Amneal Pharmaceuticals (USA),MedinCell (France) Instituting a robust process in Global Neglected Tropical Disease Treatment Market.
The Global Neglected Tropical Disease Treatment Market Study is Broken down by applications such as Schistosomiasis,Chagas disease,Leishmaniasis,Lymphatic filariasis,Onchocerciasis.
The Global Neglected Tropical Disease Treatment Market Study is segmented by Anthelmintics,Antiprotozoals,Antibiotics,Vaccines,Combination therapies.
The Global Neglected Tropical Disease Treatment Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - 2025; Base year: 2025; Forecast period: 2025 to 2033
Neglected Tropical Disease (NTD) treatments address conditions like Chagas disease, Leishmaniasis, and Lymphatic Filariasis that primarily affect low-income populations in tropical areas. Treatments include antiparasitic drugs, vaccines, and antibiotic regimens. Despite low commercial return, global health organizations and governments support R&D and distribution through donations and policy. Advances in single-dose drugs and preventive care are reshaping delivery.
